New hope for tough bone cancers: adding immune booster to chemo
NCT ID NCT03643133
Summary
This study is testing whether adding a drug called mifamurtide to standard chemotherapy after surgery helps patients with high-risk osteosarcoma (a type of bone cancer) live longer without their cancer returning. It will involve about 60 patients aged 2 to 50 who have already had initial chemotherapy and surgery. Participants will be randomly assigned to receive either standard chemotherapy alone or chemotherapy plus mifamurtide to see which approach works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Nancy - Onco-hématologie pédiatrique
Vandœuvre-lès-Nancy, France
-
CHU Amiens-Picardie - Service d'oncologie hématologie pédiatrique
Amiens, France
-
CHU Arnaud de Villeneuve - Onco-hématologie pédiatrique
Montpellier, France
-
CHU Bretonneau - Service d'oncologie médicale
Tours, France
-
CHU Toulouse - Hôpital des Enfants - Service d'Hémato-Immuno-Oncologie
Toulouse, France
-
CHU d'Angers - Service d'oncologie pédiatrique
Angers, France
-
CHU de Caen - Service d'oncologie hématologie pédiatrique
Caen, France
-
CHU de Grenoble - Service d'oncologie hématologie pédiatrique
La Tronche, France
-
CHU de Nantes - Service d'oncologie hématologie pédiatrique
Nantes, France
-
CHU de Nice - Service d'oncologie hématologie pédiatrique
Nice, France
-
Centre Eugène Marquis - Service d'oncologie médicale
Rennes, France
-
Centre Léon Bérard - IHOPE
Lyon, France
-
Centre Léon Bérard - Service d'oncologie médicale
Lyon, France
-
Centre Oscar Lambret - Unité d'onco-pédiatrie
Lille, France
-
Hôpital Armand Trousseau - Service d'hématologie et d'oncologie pédiatrique
Paris, France
-
Hôpital Charles Nicolle - Hémato-Immuno-Oncologie Pédiatrique
Rouen, France
-
Hôpital Clocheville - Hématologie et oncologie pédiatrique
Tours, France
-
Hôpital Cochin
Paris, France
-
Hôpital Hautepierre - Onco-hématologie pédiatrique
Strasbourg, France
-
Hôpital de Hautepierre - Onco-hématologie adulte
Strasbourg, France
-
Hôpital de la Timone - Service d'oncologie pédiatrique
Marseille, France
-
Hôpital de la Timone - service d'oncologie médicale
Marseille, France
-
Institut Bergonié - Service d'oncologie médicale
Bordeaux, France
-
Institut Claudius Regaud - service d'oncologie médicale
Toulouse, France
-
Institut Curie - Service d'oncologie médicale
Paris, 75000, France
-
Institut Curie - Service d'oncologie pédiatrique
Paris, France
-
Institut Gustave Roussy - Service d'oncologie médicale
Villejuif, France
-
Institut Gustave Roussy - Service de cancérologie de l'enfant et de l'adolescent
Villejuif, 94800, France
-
Institut de Cancérologie de Lorraine - Service d'oncologie médicale
Vandœuvre-lès-Nancy, France
-
Institut de Cancérologie de l'Ouest (Site René Gauducheau) - Service d'oncologie médicale
Saint-Herblain, France
-
Institut régional du Cancer de Montpellier - Service d'oncologie médicale
Montpellier, France
Conditions
Explore the condition pages connected to this study.